GLP-1 Receptor Agonists and Endoscopic Procedural Optimization: How To Minimize Risk and Improve Outcomes
- 13 June 2025
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 23 (1) , 1-9
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (T32 DK007634)
This publication has 52 references indexed in Scilit:
- Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative periodSurgical Endoscopy, 2024
- Food Retention at Endoscopy Among Adults Using Glucagon-Like Peptide-1 Receptor AgonistsJAMA Network Open, 2024
- GLP-1 Medication Use for Type 2 Diabetes Has SoaredJAMA, 2024
- Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before AnesthesiaJAMA Surgery, 2024
- Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory ComplicationsJAMA, 2024
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight LossJAMA, 2023
- Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case reportCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2023
- Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic controlDiabetologia, 2022
- Retained Food During Esophagogastroduodenoscopy Is a Risk Factor for Gastric-to-Pulmonary AspirationDigestive Diseases and Sciences, 2022
- Evaluation of the effect of GLP‐1 agonists on quality of bowel preparation for colonoscopy in patients with diabetesPractical Diabetes, 2017